[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
Showing only X posts for non-authenticated requests. Use your API key in requests for full results.
"I covered at $SPY XXXXXX and $ES 6721 in premarket trading Net Profit: + $1.03/share (5hrs @ 100%)"
X Link @RTTradingIdeas 2025-10-20T13:24Z 3966 followers, XXX engagements
"ONEOK $OKE declares $1.03/share quarterly dividend in line with previous; ex-div X Nov payable XX Nov"
X Link @dvpswe 2025-10-16T08:42Z XXX followers, XX engagements
"$NRIX Nurix Therapeutics Reports Q3 Results & Pipeline Update 🧬 Revenue: $7.9M ( from $12.6M YoY) Net Loss: ($86.4M) or ($1.03)/share Cash & Securities: $428.8M (vs. $609.6M in Nov 2024) R&D Expenses: $86.1M ( YoY from $55.5M) 🔬 Pipeline Highlights Bexobrutideg (BTK degrader): Phase X data shows ORR XXXX% in CLL and XXXX% in WM pivotal trials to start Q4 2025 (includes single-arm accelerated approval path + Phase X confirmatory study) GS-6791 (IRAK4 degrader w/ Gilead): Strong preclinical data shown at EADV 2025 demonstrating potent IRAK4 degradation and efficacy in dermatitis model"
X Link @allday_stocks 2025-10-09T20:05Z 1510 followers, XXX engagements